BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 33794753)

  • 1. Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.
    Asdemir A; Özgür A
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5167-5177. PubMed ID: 38240781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
    Smithline ZB; Nikonova AS; Hensley HH; Cai KQ; Egleston BL; Proia DA; Seeger-Nukpezah T; Golemis EA
    PLoS One; 2014; 9(12):e114403. PubMed ID: 25474361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Hsp90 Binds to and Aligns Collagen-1 to Enhance Breast Cancer Cell Invasiveness.
    Singh P; Ramanathan V; Zhang Y; Georgakoudi I; Jay DG
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888.
    Kaplan Ö
    Med Oncol; 2023 Oct; 40(11):318. PubMed ID: 37794195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells.
    Kawano M; Tanaka K; Itonaga I; Iwasaki T; Kubota Y; Tsumura H
    Oncol Res; 2023; 31(5):631-643. PubMed ID: 37547755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule heat shock protein 27 inhibitor J2 decreases ovarian cancer cell proliferation via induction of apoptotic pathways.
    Karademir D; Özgür A
    Med Oncol; 2023 Jul; 40(9):250. PubMed ID: 37493998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
    Cheon SY; Kwon S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 in Biology and Treatment of Osteosarcoma.
    Synoradzki KJ; Bartnik E; Czarnecka AM; Fiedorowicz M; Firlej W; Brodziak A; Stasinska A; Rutkowski P; Grieb P
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
    Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
    Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
    McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
    Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
    Choi HK; Lee K
    Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
    Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
    Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
    Wang Y; Trepel JB; Neckers LM; Giaccone G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
    Özgür A
    J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
    Karademir D; Özgür A
    Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.